Phase II Pilot Study: Y-90, Capecitabine & Atezolizumab in Unresectable CRC Liver Metastases (METEORITE)

Brown University is leading a single-arm phase II trial evaluating yttrium-90 radioembolization combined with capecitabine and atezolizumab for patients with oligometastatic colorectal cancer liver metastases refractory to ≥2 lines of therapy. The study aims to enhance local tumor control and systemic response in unresectable liver metastases.